Apimeds Pharmaceuticals US, Inc. (APUS) vs InMed Pharmaceuticals Inc. (INM)

Apimeds Pharmaceuticals US, Inc. and InMed Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. and InMed Pharmaceuticals Inc. are of similar size ($7.7M and $7.6M). Across the 10 metrics below, InMed Pharmaceuticals Inc. leads on 6 and Apimeds Pharmaceuticals US, Inc. on 4.

Valuation

Metric APUS INM Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S n/m 1.00 2.25
P/B 0.12 5.35 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales n/m 0.65 2.56
Earnings yield (504.41%) (218.43%) (2.99%)
Free cash flow yield (107.35%) (151.13%) 0.00%

Profitability

Metric APUS INM Drug Manufacturers Specialty & Generic median
Gross margin — 26.27% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (100.13%) (179.09%) (0.40%)
Return on assets (84.20%) (139.63%) (3.32%)
Return on invested capital (15.96%) 0.00% 0.00%

Growth

Metric APUS INM Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 19.38% 10.01%
EPS growth (last fiscal year) (205.56%) 62.68% —
Revenue growth, 5-year CAGR — — 6.74%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS INM Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.00 0.05
Current ratio 0.51 1.37 2.31
Net debt to EBITDA 0.38 0.20 0.85

Dividend

Metric APUS INM Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric APUS INM Drug Manufacturers Specialty & Generic median
Market cap 7.59m 7.69m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack